Matthew L Senjem

List of Publications by Year
in descending order

252 papers	19,630 citations	12303 69 h-index	13727 129 g-index
309 all docs	309 docs citations	309 times ranked	15241 citing authors

#	Article	IF	Citations
1	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain, 2009, 132, 1355-1365.	3.7	975
2	11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain, 2008, 131, 665-680.	3.7	819
3	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.4	581
4	An operational approach to National Institute on Agingâ€“Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology, 2012, 71, 765-775.	2.8	520
5	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133, 3336-3348.	3.7	455
6	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. NeuroImage, 2008, 39, 1186-1197.	2.1	391
7	Non-Stationarity in the â€œResting Brainâ€™sâ€•Modular Architecture. PLoS ONE, 2012, 7, e39731.	1.1	382
8	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain, 2012, 135, 794-806.	3.7	355
9	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurology, The, 2012, 11, 868-877.	4.9	355
10	Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration. Neurology, 2006, 66, 102-104.	1.5	351
11	TDP-43 is a key player in the clinical features associated with Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
12	Brain Î²-amyloid load approaches a plateau. Neurology, 2013, 80, 890-896.	1.5	335
13	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain, 2012, 135, 1522-1536.	3.7	325
14	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	3.7	309
15	Age, Sex, andAPOEÎµ4 Effects on Memory, Brain Structure, and Î²-Amyloid Across the Adult Life Span. JAMA Neurology, 2015, 72, 511.	4.5	305
16	Age-specific population frequencies of cerebral Î²-amyloidosis and neurodegeneration among people with normal cognitive function aged 50â€“89 years: a cross-sectional study. Lancet Neurology, The, 2014, 13, 997-1005.	4.9	297
17	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain, 2009, 132, 2932-2946.	3.7	277
18	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	1.4	249

#	Article	IF	Citations
19	Age-specific and sex-specific prevalence of cerebral Î²-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50â€“95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444.	4.9	241
20	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	3.8	223
21	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	3.7	222
22	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
23	Comparison of ¹⁸F-FDG and PiB PET in Cognitive Impairment. Journal of Nuclear Medicine, 2009, 50, 878-886.	2.8	183
24	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology, 2013, 81, 1732-1740.	1.5	182
25	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Agingâ€“Alzheimerâ€™s Association Research Framework. JAMA Neurology, 2019, 76, 1174.	4.5	182
26	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759.	3.7	170
27	Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. NeuroImage, 2005, 26, 600-608.	2.1	169
28	Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 2091-2105.	1.5	162
29	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162
30	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	4.9	159
31	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
32	Brain injury biomarkers are not dependent on Î²â€amyloid in normal elderly. Annals of Neurology, 2013, 73, 472-480.	2.8	155
33	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	2.1	155
34	Regional brain stiffness changes across the Alzheimer's disease spectrum. NeuroImage: Clinical, 2016, 10, 283-290.	1.4	152
35	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
36	Functional Impact of White Matter Hyperintensities in Cognitively Normal Elderly Subjects. Archives of Neurology, 2010, 67, 1379-85.	4.9	146

#	Article	IF	Citations
37	Disrupted thalamocortical connectivity in PSP: A resting-state fMRI, DTI, and VBM study. Parkinsonism and Related Disorders, 2011, 17, 599-605.	1.1	146
38	Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology, 2012, 79, 1570-1577.	1.5	146
39	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
40	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. Neurology, 2013, 81, 337-345.	1.5	142
41	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimer's and Dementia, 2015, 11, 740-756.	0.4	142
42	[¹⁸F]AVâ€1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	2.2	136
43	The evolution of primary progressive apraxia of speech. Brain, 2014, 137, 2783-2795.	3.7	134
44	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex, 2015, 69, 220-236.	1.1	133
45	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129
46	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	3.7	126
47	Measuring the Characteristic Topography of Brain Stiffness with Magnetic Resonance Elastography. PLoS ONE, 2013, 8, e81668.	1.1	125
48	Rates of Î²-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology, 2014, 82, 1605-1612.	1.5	119
49	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 2016, 132, 931-933.	3.9	116
50	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
51	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
52	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	1.5	108
53	Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. European Journal of Neurology, 2015, 22, 745-752.	1.7	106
54	Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65.	0.8	106

#	Article	IF	Citations
55	Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. Neurobiology of Aging, 2011, 32, 1531-1541.	1.5	105
56	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64.	4.9	104
57	FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimerâ€™s Type. PLoS ONE, 2013, 8, e62471.	1.1	100
58	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. Archives of Neurology, 2012, 69, 856-67.	4.9	99
59	TAR DNAâ€binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. Annals of Neurology, 2015, 78, 697-709.	2.8	96
60	MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology, 2013, 81, 126-133.	1.5	95
61	Early Postmenopausal Transdermal 17Î²-Estradiol Therapy and Amyloid-Î² Deposition. Journal of Alzheimer's Disease, 2016, 53, 547-556.	1.2	94
62	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.5	91
63	¹⁸F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. Journal of Nuclear Medicine, 2017, 58, 632-638.	2.8	91
64	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. NeuroImage, 2011, 55, 522-531.	2.1	90
65	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology, 2013, 80, 911-918.	1.5	86
66	Tauâ€PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 21-30.	1.2	86
67	Transforming cerebrospinal fluid AÎ²42 measures into calculated Pittsburgh compound B units of brain AÎ² amyloid. , 2011, 7, 133-141.		85
68	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. Neurobiology of Aging, 2015, 36, 1245-1252.	1.5	83
69	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81
70	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
71	MR Elastography Demonstrates Increased Brain Stiffness in Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2016, 37, 462-467.	1.2	77
72	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74

#	Article	IF	Citations
73	Functional magnetic resonance imaging changes in amnestic and nonamnestic mild cognitive impairment during encoding and recognition tasks. Journal of the International Neuropsychological Society, 2009, 15, 372-382.	1.2	73
74	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.5	73
75	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	2.8	73
76	Effect of intellectual enrichment on AD biomarker trajectories. Neurology, 2016, 86, 1128-1135.	1.5	71
77	Ante mortem amyloid imaging and Î²-amyloid pathology in a case with dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 878-885.	1.5	69
78	Progranulin-associated PiB-negative logopenic primary progressive aphasia. Journal of Neurology, 2014, 261, 604-614.	1.8	69
79	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	4.5	69
80	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
81	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	3.7	68
82	[¹⁸F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
83	Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: An MRI and FDG-PET study. Brain and Language, 2013, 125, 245-252.	0.8	66
84	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With Î²-Amyloidosis. JAMA Neurology, 2013, 70, 1030.	4.5	65
85	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
86	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain, 2012, 135, 2470-2477.	3.7	64
87	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. NeuroImage, 2015, 123, 149-164.	2.1	63
88	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
89	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
90	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62

#	Article	IF	Citations
91	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
92	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127.	2.1	59
93	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology, 2013, 81, 1681-1689.	1.5	58
94	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.4	58
95	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	4.5	57
96	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology, 2018, 90, e1404-e1412.	1.5	57
97	Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. Neurobiology of Aging, 2013, 34, 636-639.	1.5	54
98	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	1.4	54
99	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimerâ€™s disease presenting as logopenic progressive aphasia. Brain and Language, 2013, 127, 127-134.	0.8	53
100	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Human Brain Mapping, 2019, 40, 1618-1631.	1.9	53
101	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.5	53
102	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
103	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
104	Identification of an atypical variant of logopenic progressive aphasia. Brain and Language, 2013, 127, 139-144.	0.8	49
105	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain and Language, 2015, 142, 45-53.	0.8	49
106	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	2.8	49
107	Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment. American Journal of Neuroradiology, 2010, 31, 1247-1253.	1.2	48
108	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48

#	Article	IF	Citations
109	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. Journal of Alzheimer's Disease, 2019, 67, 181-195.	1.2	48
110	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. Neurodegenerative Diseases, 2009, 6, 106-117.	0.8	47
111	Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy. European Journal of Neurology, 2013, 20, 629-637.	1.7	47
112	Effects of hormone therapy on brain structure. Neurology, 2016, 87, 887-896.	1.5	47
113	Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology, 2013, 80, 2130-2137.	1.5	46
114	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical, 2020, 25, 102152.	1.4	46
115	Predicting functional decline in behavioural variant frontotemporal dementia. Brain, 2011, 134, 432-448.	3.7	45
116	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45
117	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1713-1724.	1.2	45
118	Protein contributions to brain atrophy acceleration in Alzheimerâ€™s disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
119	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. NeuroImage: Clinical, 2013, 2, 249-257.	1.4	44
120	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 1693-1706.	1.6	44
121	Gray matter correlates of behavioral severity in progressive supranuclear palsy. Movement Disorders, 2011, 26, 493-498.	2.2	43
122	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex, 2018, 99, 358-374.	1.1	42
123	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. Brain, 2018, 141, 302-317.	3.7	42
124	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	1.0	39
125	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. NeuroImage, 2015, 113, 61-69.	2.1	38
126	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. Brain, 2013, 136, 455-470.	3.7	37

#	Article	IF	Citations
127	White Matter Reference Region in PET Studies of ¹¹C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-Î² Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	2.8	37
128	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
129	Modeling trajectories of regional volume loss in progressive supranuclear palsy. Movement Disorders, 2013, 28, 1117-1124.	2.2	36
130	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 675-685.	0.4	36
131	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	1.5	35
132	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	1.4	34
133	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452.	5.8	34
134	[P2â€“415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.4	33
135	18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. NeuroImage: Clinical, 2018, 18, 897-902.	1.4	33
136	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	3.7	33
137	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	2.2	33
138	The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism and Related Disorders, 2014, 20, 180-185.	1.1	32
139	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
140	Sensitivityâ€“Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	2.8	32
141	Identification of Normal Pressure Hydrocephalus by Disease-Specific Patterns of Brain Stiffness and Damping Ratio. Investigative Radiology, 2020, 55, 200-208.	3.5	32
142	A computational model of neurodegeneration in Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1643.	5.8	32
143	APOE Îµ4 influences Î²â€amyloid deposition in primary progressive aphasia and speech apraxia. Alzheimer's and Dementia, 2014, 10, 630-636.	0.4	31
144	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31

#	Article	IF	Citations
145	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimerâ€™s amyloid, tau and FDG PET status. Translational Psychiatry, 2021, 11, 585.	2.4	31
146	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. Neurology, 2017, 89, 2271-2279.	1.5	30
147	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. NeuroImage: Clinical, 2017, 16, 295-302.	1.4	30
148	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
149	[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation. Journal of Neurology, 2018, 265, 1079-1088.	1.8	29
150	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain and Language, 2019, 197, 104676.	0.8	29
151	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurology, 2022, 79, 592.	4.5	29
152	Elevated occipital Î²-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1357-1364.	0.9	28
153	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	1.2	27
154	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	1.5	27
155	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 3-9.	1.1	27
156	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.5	27
157	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	4.5	27
158	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
159	Contributions of imprecision in <scp>PET</scp>â€<scp>MRI</scp> rigid registration to imprecision in amyloid <scp>PET</scp><scp>SUVR</scp> measurements. Human Brain Mapping, 2017, 38, 3323-3336.	1.9	26
160	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. Movement Disorders Clinical Practice, 2019, 6, 452-461.	0.8	26
161	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
162	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase, 2018, 24, 111-120.	0.2	25

#	Article	IF	Citations
163	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	1.7	25
164	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not aÂHomogeneous Clinical Entity. Journal of Alzheimer's Disease, 2016, 55, 1019-1029.	1.2	24
165	Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women. Journal of Neurology, 2017, 264, 938-945.	1.8	24
166	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.5	24
167	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
168	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	4.5	23
169	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.5	22
170	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex, 2017, 90, 138-148.	1.1	22
171	[ICâ€Pâ€122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN. Alzheimer's and Dementia, 2017, 13, P93.	0.4	22
172	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
173	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
174	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	1.5	20
175	TDP-43 and Alzheimerâ€™s Disease Pathologic Subtype in Non-Amnestic Alzheimerâ€™s Disease Dementia. Journal of Alzheimer's Disease, 2018, 64, 1227-1233.	1.2	20
176	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
177	Multimodal neuroimaging relationships in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 56-61.	1.1	19
178	Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 28, 29-35.	1.1	18
179	Investigation of white matter PiB uptake as a marker of white matter integrity. Annals of Clinical and Translational Neurology, 2019, 6, 678-688.	1.7	18
180	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18

#	Article	IF	Citations
181	Regional Î²â€amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia. European Journal of Neurology, 2016, 23, 313-319.	1.7	17
182	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
183	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	2.8	17
184	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
185	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. Brain and Language, 2020, 204, 104773.	0.8	15
186	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	2.1	15
187	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
188	Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2014, 10, 62-66.	0.4	14
189	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
190	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
191	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
192	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
193	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202.	1.5	13
194	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. NeuroImage: Clinical, 2021, 32, 102850.	1.4	13
195	Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech. European Journal of Neurology, 2018, 25, 1352-1357.	1.7	12
196	Neural correlates of domain-specific cognitive decline. Neurology, 2019, 92, e1051-e1063.	1.5	12
197	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12
198	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	1.5	12

#	Article	IF	Citations
199	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. Neurology, 2022, 98, .	1.5	12
200	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	1.5	11
201	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
202	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. Journal of Neurology, 2015, 262, 2064-2072.	1.8	10
203	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. NeuroImage: Clinical, 2016, 11, 90-98.	1.4	10
204	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
205	Amyloid burden correlates with cognitive decline in Alzheimer's disease presenting with aphasia. European Journal of Neurology, 2014, 21, 1040-1043.	1.7	9
206	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. Scientific Reports, 2018, 8, 7421.	1.6	9
207	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	1.5	9
208	Phonological Errors in Posterior Cortical Atrophy. Dementia and Geriatric Cognitive Disorders, 2021, 50, 195-203.	0.7	8
209	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
210	Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	1.2	7
211	Impact of material homogeneity assumption on cortical stiffness estimates by <scp>MR</scp> elastography. Magnetic Resonance in Medicine, 2022, 88, 916-929.	1.9	7
212	Comparison of ¹¹C-Pittsburgh Compound B and ¹⁸F-Flutemetamol White Matter Binding in PET. Journal of Nuclear Medicine, 2022, 63, 1239-1244.	2.8	7
213	APOE Îµ4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 784-796.	0.4	7
214	Face recognition from research brain PET: An unexpected PET problem. NeuroImage, 2022, 258, 119357.	2.1	6
215	Sleep quality and cortical amyloid-Î² deposition in postmenopausal women of the Kronos early estrogen prevention study. NeuroReport, 2021, 32, 326-331.	0.6	5
216	The Overlap Index as a means of evaluating early tau-PET signal reliability. Journal of Nuclear Medicine, 2022, , jnumed.121.263136.	2.8	5

#	Article	IF	Citations
217	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Communications, 2022, 4, .	1.5	5
218	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.3	4
219	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphereâ€"Predominant Logopenic Progressive Aphasia. Neurology, 2021, 97, e523-e534.	1.5	4
220	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675.	2.2	4
221	CSF phosphorylated tau as an indicator of subsequent tau accumulation. Neurobiology of Aging, 2022, 117, 189-200.	1.5	4
222	ICâ€Pâ€127: VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR. Alzheimer's and Dementia, 2019, 15, P104.	0.4	3
223	Multiple sclerosis is associated with lower amyloid but normal tau burden on PET. Alzheimer's and Dementia, 2020, 16, e039179.	0.4	3
224	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	1.5	3
225	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	2.1	3
226	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	1.4	3
227	Leftâ€"Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T 1 Weighted MRI Images. Journal of Magnetic Resonance Imaging, 2022, , .	1.9	3
228	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2021, , .	1.2	2
229	O2â€07â€01: SLEEP QUALITY AND BETAâ€AMYLOID DEPOSITION IN RECENTLY MENOPAUSAL WOMEN PARTICIPATING IN THE KRONOS EARLY ESTROGEN PREVENTION STUDY (KEEPS). Alzheimer's and Dementia, 2019, 15, P551.	0.4	1
230	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: A description of 55 cases and comparisons to other clinical AD phenotypes. Alzheimer's and Dementia, 2020, 16, e040622.	0.4	1
231	Asymmetric caudate hypometabolism in the absence of frontal involvement on FDGâ€PET in patients with semantic dementia and behavioral symptoms. Alzheimer's and Dementia, 2020, 16, e045393.	0.4	1
232	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6.	1.2	1
233	Relationship of APOE , age, amyloid and clinical phenotype in Alzheimer disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
234	O2â€08â€01: ANTEâ€MORTEM VOLUME LOSS MIRRORS TDP43 STAGING IN NONâ€FTLD OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P553.	0.4	0

#	Article	IF	Citations
235	ICâ€Pâ€078: ALTERED CSF DYNAMICS INFLUENCE DISCREPANCIES BETWEEN CSF AND PET BIOMARKERS OF AMYLOID. Alzheimer's and Dementia, 2019, 15, P70.	0.4	0
236	O4â€12â€01: TAU PET IMAGING CORRELATES WITH NEUROPATHOLOGY. Alzheimer's and Dementia, 2019, 15, P1264.	0.4	0
237	ICâ€02â€03: MILD COGNITIVE IMPAIRMENT PROGRESSING TO DEMENTIA WITH LEWY BODIES: REGIONAL ATROPHY RATES AND RELATIONSHIP TO AVâ€1451 UPTAKE. Alzheimer's and Dementia, 2019, 15, P2.	0.4	0
238	ICâ€04â€02: ANTEMORTEM VOLUME LOSS MIRRORS TDP43 STAGING IN NONâ€FTLD OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P5.	0.4	0
239	ICâ€Pâ€022: BRAIN STATES AND TAU PET PATTERNS INTERACT ACROSS THE AGINGâ€ALZHEIMER'S CONTINUUM. Alzheimer's and Dementia, 2019, 15, P30.	0.4	0
240	ICâ€Pâ€027: DECODING GLUCOSE METABOLISM IN ALZHEIMER'S DISEASE REVEALS MACROâ€SCALE BRAIN ORGANIZATION RELATED TO DISEASE EXPRESSION. Alzheimer's and Dementia, 2019, 15, P34.	0.4	0
241	Functional connectivity is associated with tau spreading in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e037681.	0.4	0
242	Disrupted brain dynamics across the Alzheimerâ€™s disease spectrum is related to tau accumulation. Alzheimer's and Dementia, 2020, 16, e040583.	0.4	0
243	Effect of disproportionately enlarged subarachnoid space hydrocephalus (DESH) on cognition. Alzheimer's and Dementia, 2020, 16, e042304.	0.4	0
244	Quantitative susceptibility mapping of substantia nigra in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e046236.	0.4	0
245	CD33 , MEF2C , and SORL1 are associated with variability in macroscale functional brain architecture in AD. Alzheimer's and Dementia, 2020, 16, e046573.	0.4	0
246	Neuroimaging and neuropsychological findings in MAPT N279K mutation phenoconverters. Alzheimer's and Dementia, 2020, 16, e046759.	0.4	0
247	The Overlap Index: A new means for early detection of serial tau PET signal change. Alzheimer's and Dementia, 2021, 17, .	0.4	0
248	Comparison of Pittsburgh compoundâ€B and flutemetamol white matter binding. Alzheimer's and Dementia, 2021, 17, .	0.4	0
249	Baseline CSF phosphorylated tau as an indicator of subsequent tau accumulation on tau PET. Alzheimer's and Dementia, 2021, 17, .	0.4	0
250	Optimizing software methods for measuring flortaucipir SUVR change over time. Alzheimer's and Dementia, 2021, 17, .	0.4	0
251	Higher systolic and diastolic blood pressures are associated with loss of white matter integrity in postmenopausal women of the KEEPS Continuation Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
252	An examination of atypical primary progressive aphasia variants. Alzheimer's and Dementia, 2021, 17, .	0.4	0